Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Temsirolimus in pediatric relapsed/refractory solid tumors
NCT00106353Phase 2Completed
- Sponsor
- Pfizer
- Start
- Mar 2005
- Primary completion
- Oct 2009
- Modality
- Small Molecules
- Countries
- 7
01
Overview
Phase 2, open-label, single-arm trial of temsirolimus in solid tumor, neuroblastoma, rhabdomyosarcoma (RMS) and 1 more, sponsored by Pfizer. Primary endpoints: Number of Participants With Adverse Events (AEs) and Serious Adverse Events (SAEs), Number of Participants With Drug Related Treatment Emergent Adverse Events (TEAEs) and 2 more. Started Mar 2005; status: completed.
02
Drugs
temsirolimus
03
Conditions
solid tumorneuroblastomarhabdomyosarcoma (RMS)glioma
Beyond the preview
Go deeper on NCT00106353.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00106353.